IDBS Blog | 23rd August 2011
The Truth. The Whole Truth. And Nothing but the Truth
Why the world needs to get real about how we treat data for INDs
It goes without saying that preclinical collaboration is complex business. So why then is so much of the historical data, collected over so many years of intensive research, so problematical to actually use and collaborate with?
More than ever before the industry needs a “Single Point of Truth” – an authoritative datasource that every member of the chain can access and use as they need at every stage of IND development.
There are three key goals that customers tell us they need to achieve:
“Every group in my community must be allowed (and have the ability) to collaborate via data.”
“We have to find a way to use historical data more intelligently to improve the speed and quality of the whole process.”
“We’re crying out for a way to simplify the production and validation of IND submission.”
We believe that better use of data can be delivered today – cost effectively and efficiently – if we use the right approach and a data-centric information system that already exists. So if you’re looking for some real world answers to improving IND data delivery read on
More news
Ensuring product, process and patient data integrity and traceability throughout the BioPharmaceutical lifecycle in the era of personalized medicine
The BioPharma industry is facing a multitude of challenging external trends, from the growth in personalized medicine to supply chain disruptions and more.
European Biomanufacturing Summit 2023
Come and join us at booth 130 in Amsterdam, to learn how an innovative tech transfer approach can revolutionize drug manufacturing in the pharmaceutical industry.
IDBS events roundup: Q1 highlights and Q2 events
IDBS associates had the opportunity to attend some events in Q1 and attendees were eager to see, hear and learn more about what’s happening in the industry.
How to improve time-to-value using GxP computer systems
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.